Related Experiment Video

Updated: May 8, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Discovery, synthesis and biological evaluation of cycloprotoberberine derivatives as potential antitumor agents

Yang-Biao Li1, Wu-Li Zhao, Yan-Xiang Wang

  • 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China.

European Journal of Medicinal Chemistry
|September 10, 2013
PubMed

Insights

New cycloprotoberberine derivatives show potent antitumor activity. Compound 7f effectively targets drug-resistant cancer cells by inhibiting DNA topoisomerases, offering a promising new therapeutic strategy.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Developing novel anticancer agents is crucial to overcome drug resistance.
  • Cycloprotoberberine scaffolds represent a potential class of antitumor compounds.

Purpose of the Study:

  • To design, synthesize, and evaluate new 1,13-cycloprotoberberine derivatives for cytotoxic activity.
  • To investigate the structure-activity relationship (SAR) and mechanism of action of promising compounds.

Main Methods:

  • Synthesis of 1,13-cycloprotoberberine derivatives with variations at the 9-position.
  • In vitro cytotoxicity assays against HepG2, HT1080, HCT116, and MCF-7/ADrR cancer cell lines.
  • Mechanism studies including DNA topoisomerase inhibition assays and cell cycle analysis.

Main Results:

  • Several derivatives exhibited significant antiproliferative activity.
  • Compound 7f showed equipotent cytotoxicity against parent and doxorubicin-resistant MCF-7 cells.
  • Compound 7f inhibited DNA topoisomerase I and II, leading to G2/M phase arrest and reduced tumor cell growth.

Conclusions:

  • Ester moiety replacement at the 9-position enhances antiproliferative activity.
  • Cycloprotoberberine analogues are promising antitumor agents, effective against drug-resistant cancer cells.
  • Compound 7f exhibits a distinct mechanism of action, targeting DNA topoisomerases.
Keywords:
AntiproliferativeCycloprotoberberineDrug resistanceStructure−activity relationshipTopoisomerase

More Related Videos

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...